Mereo BioPharma shifts focus to rare diseases with setrusumab showing strong results for Osteogenesis Imperfecta. Learn more on MREO stock here.

California, USA-based rare disease company Ultragenyx Pharmaceutical (Nasdaq: RARE) yesterday released new data demonstrating treatment with UX111 (ABO-102) AAV gene therapy led to a ...

Goldman Sachs, maintaining a Buy rating on Ultragenyx, has expressed confidence in the company's Phase 3 Orbit study of setrusumab for osteogenesis imperfecta. The firm also anticipates further ...

Rubric says Mereo has a "bedrock" asset with anti-sclerostin IgG2 monoclonal antibody setrusumab for rare bone disease osteogenesis imperfecta, which was partnered in the US with Ultragenyx in a ...

Orbit Phase 3 study of setrusumab in osteogenesis imperfecta continuing to planned second interim analysis, expected in mid-2025 Alvelestat, for Alpha-1 Antitrypsin Deficiency-associated Lung Disease, ...

The Phase 3 portion of the pivotal Phase 2/3 Orbit study is evaluating the effect of setrusumab compared to placebo on clinical fracture rate in patients aged five to under 26. The newly initiated ...

Ultragenyx's pipeline is rich with promising candidates, with setrusumab for osteogenesis imperfecta (OI) and GTX-102 for Angelman syndrome leading the charge. Setrusumab, currently in Phase 3 ...